Study of Stapokibart Injection in Patients With Allergic Rhinitis

Inclusion Criteria:

• Able to understand the study and voluntarily sign the Informed consent form.

• Diagnosed Allergic Rhinitis according to the Criteria stated in the ChineseGuidelines for the Diagnosis and Treatment of Allergic Rhinitis (2022, RevisedEdition).

• Subjects with asthma must be evaluated by the researcher as having a stablecondition.

• Has a positive skin prick test (SPT) or positive antigen-specific serumimmunoglobulin E (IgE).

Exclusion Criteria:

• Use of anti-interleukin 4 receptor alpha subunit (IL-4Rα) monoclonal antibody,thymic stromal lymphopoietin (TSLP) monoclonal antibody, anti-IgE monoclonalantibody, other monoclonal antibodies, or other biologics within 10 weeks or 5half-lives (whichever is longer) prior to the screening visit.

• Use of any investigational product within 4 weeks prior to the screening visit orplanning to participate in other clinical studies during this study.

• Forced expiratory volume in 1 second (FEV1) ≤ 50% of the predicted value during thescreening/run-in period.

• Have acute sinusitis, nasal infection, or upper respiratory tract infection atscreening or within 2 weeks prior to screening.

• Have received a live-attenuated vaccine within 12 weeks prior to randomization orplanning to receive one during the study.